Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Enterprise Value (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Enterprise Value for 7 consecutive years, with -$848.3 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 73.56% to -$848.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$848.3 million through Dec 2025, down 73.56% year-over-year, with the annual reading at -$848.3 million for FY2025, 73.56% down from the prior year.
  • Enterprise Value for Q4 2025 was -$848.3 million at Kymera Therapeutics, down from -$505.7 million in the prior quarter.
  • The five-year high for Enterprise Value was -$33.7 million in Q1 2022, with the low at -$848.3 million in Q4 2025.
  • Average Enterprise Value over 5 years is -$448.3 million, with a median of -$462.2 million recorded in 2021.
  • The sharpest move saw Enterprise Value surged 89.89% in 2022, then crashed 1076.52% in 2023.
  • Over 5 years, Enterprise Value stood at -$442.4 million in 2021, then rose by 7.97% to -$407.2 million in 2022, then rose by 7.93% to -$374.9 million in 2023, then plummeted by 30.37% to -$488.7 million in 2024, then crashed by 73.56% to -$848.3 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$848.3 million, -$505.7 million, and -$665.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.